There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioCryst (BCRX – Research Report), Lineage Cell Therapeutics (LCTX – Research Report) and Sarepta Therapeutics (SRPT – Research Report) with bullish sentiments. BioCryst (BCRX) In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on BioCryst, with a price target of $13.00. The company's shares closed last Thursday at $7.89, close to its 52-week low of $7.61. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biocryst-bcrx-lineage-cell-therapeutics-lctx-and-sarepta-therapeutics-srpt?utm_source=advfn.com&utm_medium=referral
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Sarepta Therapeutics Charts.
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Sarepta Therapeutics Charts.